Group Medical Visits for 144 Dyslipidemia Patients
Summary
NIH has registered a new clinical trial (NCT07543718) evaluating group medical visits (GMVs) as an implementation strategy for 144 patients with dyslipidemia, the primary driver of cardiovascular disease. The study will follow the RE-AIM framework to assess adoption, implementation, and health outcomes, with the goal of positioning the research team to conduct larger-scale lifestyle medicine studies. This registry entry documents the study design, participant conditions (Dyslipidemias), and planned interventions (Group medical visits) ahead of an anticipated April 2026 start date.
“In this context, GMVs will be implemented among 144 patients with dyslipidemia.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NIH has registered a new clinical trial (NCT07543718) titled 'Group Medical Visits for Patients With Dyslipidemia' on ClinicalTrials.gov, planned for 144 adult patients with dyslipidemia. The study will implement group medical visits as a physician-delivered intervention to overcome barriers (time, confidence, compensation) that limit lifestyle counseling in primary care, and will evaluate implementation using the RE-AIM framework.
This registry entry does not impose compliance obligations on any party. Healthcare providers interested in lifestyle medicine delivery models, and researchers studying cardiovascular disease prevention strategies, should monitor the trial's progress for future evidence on GMV effectiveness in dyslipidemia populations.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Group Medical Visits for Patients With Dyslipidemia
N/A NCT07543718 Kind: NA Apr 22, 2026
Abstract
Physicians' interventions to promote the improvement of lifestyle habits have been shown to be effective. However, such interventions remain underutilized due to barriers such as lack of time, confidence, and compensation. Group medical visits (GMVs) can help overcome several of these barriers and effectively improve clinical indicators as well as patients' quality of life. GMVs could also reduce pressure on the healthcare system by improving access to primary care through a more efficient use of resources. The literature suggests that GMVs can be effective in improving access to care and reducing disease complications for patients with several conditions and risk factors, but they have not been assessed specifically among patients with dyslipidemia, which is at the origin of most cases of cardiovascular diseases. In this context, GMVs will be implemented among 144 patients with dyslipidemia. The objective for this project is to evaluate implementation of GMVs. The implementation evaluation will follow the RE-AIM framework. These steps will position the research team to develop more complex and large-scale studies in lifestyle medicine. In the meantime, the project will contribute to improve access to primary care for the prevention of cardiovascular diseases.
Conditions: Dyslipidemias
Interventions: Group medical visits
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.